SPAC8E11.12 Antibody

What is SPAC8E11.12 and why is it significant in fission yeast research?

SPAC8E11.12 is a gene in Schizosaccharomyces pombe (fission yeast) that encodes a putative sorbose reductase . This protein remains largely uncharacterized but has appeared in several large-scale proteomic studies, including those examining protein-protein interactions and chromatin remodeling . Its significance lies in understanding basic cellular processes in S. pombe, which serves as an important model organism for eukaryotic cell biology studies. The protein has been included in several comprehensive studies examining proteome-wide interactions in fission yeast , suggesting potential roles in fundamental cellular processes.

What experimental applications are validated for SPAC8E11.12 antibodies?

Based on available product information, SPAC8E11.12 antibodies have been validated for ELISA and Western blot applications . These applications enable researchers to detect the presence and relative abundance of the SPAC8E11.12 protein in experimental samples. When designing experiments, researchers should note that validation documentation for this relatively specialized antibody may be limited compared to antibodies targeting more widely-studied proteins. For optimal results, preliminary validation experiments should be conducted within your specific experimental system.

How should SPAC8E11.12 antibody specificity be verified before experimental use?

Antibody specificity for SPAC8E11.12 should be verified using a multi-method approach:

• Western blot analysis using wild-type S. pombe lysate compared to SPAC8E11.12 deletion mutants

• Immunoprecipitation followed by mass spectrometry to confirm target capture

• Peptide competition assays to demonstrate binding specificity

According to established antibody validation frameworks , at least one orthogonal method should be used to validate antibody specificity. For SPAC8E11.12, this could involve correlating protein detection with mRNA expression data from existing S. pombe transcriptome datasets.

What are the optimal sample preparation protocols for detecting SPAC8E11.12 in S. pombe lysates?

For effective SPAC8E11.12 detection in S. pombe samples:

• Harvest cells during logarithmic growth phase (OD600 ~0.5-0.8) to ensure consistent protein expression

• Use a lysis buffer containing 50 mM HEPES (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, and protease inhibitor cocktail

• Disrupt cells using glass beads (0.5 mm) with 5-7 cycles of vortexing (30 seconds) and cooling on ice (30 seconds)

• Clear lysates by centrifugation at 15,000 × g for 15 minutes at 4°C

• For Western blotting, load 20-50 μg of total protein per lane

This protocol is based on general practices for yeast protein analysis, as S. pombe proteins often require stringent extraction methods due to their cell wall structure. The effectiveness of this approach may require optimization for SPAC8E11.12, particularly as it is not one of the most abundantly expressed proteins in the yeast proteome.

How can researchers overcome cross-reactivity challenges when using SPAC8E11.12 antibodies?

To minimize cross-reactivity issues with SPAC8E11.12 antibodies:

• Perform pre-adsorption of the antibody with S. pombe lysate from SPAC8E11.12 deletion strains

• Use extended blocking steps (2 hours minimum) with 5% BSA or milk in TBST

• Include additional wash steps (at least 5 × 5 minutes) with 0.1% Tween-20 in TBS

• Titrate antibody concentrations carefully, generally starting with higher dilutions (1:2000) and adjusting based on signal-to-noise ratio

• Consider using knockout controls in parallel with all experiments to definitively identify non-specific bands

This approach follows established methods for enhancing antibody specificity in challenging experimental systems , and accounts for the likelihood that uncharacterized proteins may share epitopes with other yeast proteins.

How can SPAC8E11.12 antibodies be integrated into high-throughput proteomic workflows?

For high-throughput proteomic applications using SPAC8E11.12 antibodies:

• Adapt the antibody for use in IP-MS workflows following protocols similar to those described in large-scale antibody studies

• For IP-MS, conjugate the antibody to magnetic beads (typically 5-10 μg antibody per 50 μl bead slurry) using standard crosslinking chemistry

• Develop a standardized analysis pipeline that includes:

  • Quantification of SPAC8E11.12 peptide intensities across conditions

  • Statistical analysis to determine significant interaction partners

  • Network analysis to place SPAC8E11.12 in functional protein clusters

This approach draws on established protocols for antibody-based proteomic studies , adapted for the specific challenges of working with a yeast protein. Researchers should be aware that optimization will be required due to the limited characterization of SPAC8E11.12 interaction networks.

What controls are essential when using SPAC8E11.12 antibodies for chromatin immunoprecipitation experiments?

For ChIP experiments using SPAC8E11.12 antibodies, implement these essential controls:

• Input control: 5-10% of pre-immunoprecipitated chromatin to normalize for DNA abundance

• IgG control: Non-specific IgG from the same species as the SPAC8E11.12 antibody

• No-antibody control: Beads-only precipitation to detect non-specific DNA binding

• SPAC8E11.12 deletion strain: To establish background signal levels

• Positive control: Precipitation of a well-characterized chromatin-associated protein (e.g., histone H3)

• Negative control: Amplification of a genomic region not expected to associate with SPAC8E11.12

These controls align with recommendations for ChIP protocols and are particularly important for SPAC8E11.12, as its chromatin association has been suggested in studies of chromatin remodeling complexes but requires further characterization.

How should researchers interpret variable detection levels of SPAC8E11.12 across different growth conditions?

When analyzing variable SPAC8E11.12 detection across experimental conditions:

• Normalize protein levels to multiple loading controls appropriate for yeast (e.g., PSTAIR/Cdc2, actin, and tubulin)

• Correlate protein detection with SPAC8E11.12 mRNA expression data from similar conditions

• Consider post-translational modifications that might affect epitope accessibility:

  • Phosphorylation status, especially in response to metabolic changes

  • Ubiquitination, which may signal protein degradation

• Evaluate cell cycle-dependent expression patterns, as many S. pombe proteins show cell cycle regulation

• Account for potential strain-specific variations in expression levels

This analytical approach acknowledges that SPAC8E11.12 has been identified in studies examining phosphorylation-dependent processes and may be subject to condition-specific regulation that affects detection by antibodies.

What technical challenges are specific to immunofluorescence applications with SPAC8E11.12 antibodies?

For immunofluorescence using SPAC8E11.12 antibodies, researchers should address these specific challenges:

• Cell wall permeabilization: S. pombe requires more stringent permeabilization than mammalian cells

  • Use enzymatic digestion with zymolyase (1 mg/ml, 30 minutes at 30°C)

  • Follow with 0.5% Triton X-100 treatment (10 minutes)

• Fixation optimization: Test multiple fixation protocols

  • 4% paraformaldehyde (10 minutes) followed by methanol (-20°C, 6 minutes)

  • 3.7% formaldehyde with 0.2% glutaraldehyde for improved structural preservation

• Background reduction:

  • Pre-absorb antibodies against fixed, permeabilized SPAC8E11.12 deletion strains

  • Include 0.1% BSA and 0.1% Tween-20 in all antibody dilution and wash buffers

• Signal amplification for low-abundance proteins:

  • Consider tyramide signal amplification if conventional secondary antibody detection yields poor signal

  • Use high-sensitivity detection systems with longer exposure times

These approaches address the known challenges of immunofluorescence in yeast cells, particularly for potentially low-abundance proteins like SPAC8E11.12.

How does the validation approach for SPAC8E11.12 antibodies compare to enhanced validation strategies used for other research antibodies?

When comparing SPAC8E11.12 antibody validation to enhanced validation strategies:

This comparative framework draws on established enhanced validation criteria and highlights the particular importance of genetic validation for lesser-studied proteins like SPAC8E11.12, where multiple commercial antibodies may not be available.

How can researchers integrate SPAC8E11.12 antibody data with other -omics approaches for more comprehensive functional studies?

For integrating SPAC8E11.12 antibody data with other -omics approaches:

• Correlate protein expression data with:

  • Transcriptome profiling (RNA-seq) to identify discrepancies between mRNA and protein levels

  • Phosphoproteome analysis to determine potential regulatory phosphorylation sites

  • Interactome studies to place SPAC8E11.12 in functional protein networks

• Implement computational strategies:

  • Use pathway enrichment analysis with identified interaction partners

  • Apply gene ontology analysis to predict cellular functions

  • Utilize cross-species homology mapping to infer functions from better-characterized homologs

• Develop integrated visualization:

  • Create network diagrams that integrate protein-protein interaction data with transcriptional regulation

  • Implement temporal mapping of expression patterns across conditions

  • Generate subcellular localization maps based on fractionation and imaging data

This multi-omics approach follows current best practices in systems biology and can help position SPAC8E11.12 within the broader cellular context, despite its currently limited characterization.